• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

对《治疗定位报告》中关于老年心房颤动患者口服抗凝治疗建议的依从性。ESPARTA 研究。

Adherence to recommendations of the Therapeutic Positioning Report about treatment with oral anticoagulants in elderly patients with atrial fibrillation. The ESPARTA study.

机构信息

Servicio de Medicina Interna, Hospital Universitario de La Princesa, Madrid, España.

Servicio de Medicina Interna, Hospital Carlos III, Madrid, España.

出版信息

Med Clin (Barc). 2018 Jul 13;151(1):8-15. doi: 10.1016/j.medcli.2017.07.025. Epub 2017 Oct 6.

DOI:10.1016/j.medcli.2017.07.025
PMID:28992980
Abstract

BACKGROUND AND OBJECTIVE

To evaluate the adherence to the recommendations in clinical practice performed by the Therapeutic Positioning Report (TPR) of the Spanish Agency of Medicines and Sanitary Products about the treatment with oral anticoagulants in patients aged≥75 years old with nonvalvular atrial fibrillation (NVAF) treated in Internal Medicine departments in Spain.

PATIENTS AND METHODS

Observational, cross-sectional and multicenter study in which 837 patients aged≥75 years old with NVAF, with stable treatment with oral anticoagulants at least 3 months before inclusion, and that had started treatment with oral anticoagulants before the inclusion period were included.

RESULTS

Mean age was 83.0±5.0 years old, mean CHADS score 3.2±1.2, mean CHADS-VASc score 5.0±1.4, and mean HAS-BLED score 2.1±0.9. A percentage of 70.8 of patients were treated with vitamin K antagonists (VKA) and the rest of patients with direct oral anticoagulants (DOACs). A percentage of 65.6 of patients treated with VKA did not follow the recommendations made by the TPR compared with 43.0% of patients treated with DOACs (P<.0001). In the case of VKA, the main reason for being considered as not appropriate according to the TPR was having poor control of anticoagulation and not switching to DOACs, whereas in the case of DOACs, it was not receiving the adequate dose according to the TPR.

CONCLUSIONS

In a high proportion of anticoagulated elderly patients with NVAF in Spain, the recommendations performed by the TPR are not followed, particularly with VKA, since patients are not switched to DOACs despite time in therapeutic range.

摘要

背景与目的

评估西班牙药品和医疗产品管理局关于非瓣膜性心房颤动(NVAF)治疗的治疗定位报告(TPR)中关于≥75 岁老年患者口服抗凝剂治疗的建议在西班牙内科部门的临床实践中的遵循情况。

患者与方法

这是一项观察性、横断面和多中心研究,共纳入 837 名≥75 岁、NVAF 稳定、至少在纳入前 3 个月开始口服抗凝治疗且在纳入期前开始口服抗凝治疗的患者。

结果

平均年龄为 83.0±5.0 岁,平均 CHADS 评分为 3.2±1.2,平均 CHADS-VASc 评分为 5.0±1.4,平均 HAS-BLED 评分为 2.1±0.9。70.8%的患者接受维生素 K 拮抗剂(VKA)治疗,其余患者接受直接口服抗凝剂(DOACs)治疗。与接受 DOACs 治疗的患者(43.0%)相比,接受 VKA 治疗的患者中,有 65.6%的患者未遵循 TPR 提出的建议(P<.0001)。在 VKA 组中,根据 TPR 认为不合适的主要原因是抗凝控制不佳且未转换为 DOACs,而在 DOACs 组中,原因是未根据 TPR 给予适当剂量。

结论

在西班牙接受 NVAF 治疗的老年抗凝患者中,很大一部分患者未遵循 TPR 提出的建议,尤其是 VKA 组,尽管患者的治疗范围符合要求,但并未转换为 DOACs。

相似文献

1
Adherence to recommendations of the Therapeutic Positioning Report about treatment with oral anticoagulants in elderly patients with atrial fibrillation. The ESPARTA study.对《治疗定位报告》中关于老年心房颤动患者口服抗凝治疗建议的依从性。ESPARTA 研究。
Med Clin (Barc). 2018 Jul 13;151(1):8-15. doi: 10.1016/j.medcli.2017.07.025. Epub 2017 Oct 6.
2
[Use of non-vitamin K antagonist oral anticoagulants in Primary Care: ACTUA study].[基层医疗中使用非维生素K拮抗剂口服抗凝剂:ACTUA研究]
Semergen. 2017 Oct;43(7):477-485. doi: 10.1016/j.semerg.2016.09.003. Epub 2016 Oct 29.
3
[Use of direct-acting oral anticoagulants in Primary Care in Spain. Positioning statement by SEMERGEN on the current situation].[西班牙基层医疗中直接口服抗凝剂的使用。西班牙初级保健医疗服务协会(SEMERGEN)对当前形势的立场声明]
Semergen. 2019 Sep;45(6):413-429. doi: 10.1016/j.semerg.2019.06.002. Epub 2019 Jul 19.
4
Patients with non-valvular atrial fibrillation on vitamin k antagonists or direct-acting oral anticoagulants: patients profile and long-term follow up outcomes.接受维生素K拮抗剂或直接口服抗凝剂治疗的非瓣膜性心房颤动患者:患者概况及长期随访结果
Arch Cardiol Mex. 2019;89(4):382-392. doi: 10.24875/ACM.19000023.
5
Direct oral anticoagulants versus vitamin K antagonists in real-world patients with nonvalvular atrial fibrillation. The FANTASIIA study.真实世界中非瓣膜性心房颤动患者使用直接口服抗凝剂与维生素K拮抗剂的比较。FANTASIIA研究。
Rev Esp Cardiol (Engl Ed). 2020 Jan;73(1):14-20. doi: 10.1016/j.rec.2019.02.021. Epub 2019 May 31.
6
[Current situation of direct oral anticoagulants in primary care in Spain: Positioning of SEMERGEN in 2023].[西班牙基层医疗中直接口服抗凝剂的现状:2023年西班牙初级保健医生协会(SEMERGEN)的立场]
Semergen. 2024 Apr;50(3):102136. doi: 10.1016/j.semerg.2023.102136. Epub 2023 Dec 5.
7
Type and doses of oral anticoagulants and adherence to anticoagulant treatment in elderly patients with atrial fibrillation: the ESPARTA study.老年房颤患者口服抗凝药的类型和剂量以及抗凝治疗的依从性:ESPARTA研究
J Comp Eff Res. 2018 Mar;7(3):223-232. doi: 10.2217/cer-2017-0034. Epub 2018 Feb 21.
8
Anticoagulation Control in Patients With Nonvalvular Atrial Fibrillation Attended at Primary Care Centers in Spain: The PAULA Study.西班牙初级保健中心非瓣膜性心房颤动患者的抗凝控制:PAULA研究
Rev Esp Cardiol (Engl Ed). 2015 Sep;68(9):769-76. doi: 10.1016/j.rec.2015.04.017. Epub 2015 Jul 11.
9
Profiling of patients with non-valvular atrial fibrillation and moderate-to-high risk of stroke not receiving oral anticoagulation in Spain.西班牙未接受口服抗凝治疗的非瓣膜性心房颤动且中风风险为中到高危患者的特征分析。
Semergen. 2019 Sep;45(6):396-405. doi: 10.1016/j.semerg.2018.10.005. Epub 2018 Dec 17.
10
Demographic, clinical, and functional determinants of antithrombotic treatment in patients with nonvalvular atrial fibrillation.非瓣膜性心房颤动患者抗血栓治疗的人口学、临床和功能决定因素。
BMC Cardiovasc Disord. 2021 Aug 9;21(1):384. doi: 10.1186/s12872-021-02019-0.

引用本文的文献

1
Framing anticoagulation control according to clinical practice for patients with atrial fibrillation in Spain: a multidisciplinary vision trough AMFA Project.根据西班牙心房颤动患者的临床实践制定抗凝控制方案:通过AMFA项目的多学科视角
Front Cardiovasc Med. 2025 Mar 5;12:1426072. doi: 10.3389/fcvm.2025.1426072. eCollection 2025.
2
Consequences of the Poor Anticoagulation Control of Patients with Non-Valvular Atrial Fibrillation Treated with Vitamin K Antagonists.维生素K拮抗剂治疗的非瓣膜性心房颤动患者抗凝控制不佳的后果。
J Clin Med. 2024 Oct 30;13(21):6495. doi: 10.3390/jcm13216495.
3
Long-Term Anticoagulation in Secondary Ischemic Stroke Prevention: The Prospective Multicenter RESTAIC Registry.
二级缺血性卒中预防中的长期抗凝治疗:前瞻性多中心RESTAIC注册研究
Front Neurol. 2020 Oct 19;11:575634. doi: 10.3389/fneur.2020.575634. eCollection 2020.
4
[Therapeutic positioning reports: Experience in Spain during the period 2013-2019].[治疗性体位报告:2013 - 2019年期间西班牙的经验]
Aten Primaria. 2020 Dec;52(10):697-704. doi: 10.1016/j.aprim.2020.02.012. Epub 2020 May 4.
5
Clinical profile and management of rivaroxaban in patients with atrial fibrillation in routine practice in Spain: data from six nationwide studies.西班牙常规实践中利伐沙班用于房颤患者的临床特征与管理:六项全国性研究的数据
Drugs Context. 2019 Oct 9;8:212606. doi: 10.7573/dic.212606. eCollection 2019.
6
Clinical characteristics and type of antithrombotic treatment in a Spanish cohort of elderly patients with atrial fibrillation according to dependency, frailty and cognitive impairment.西班牙一组老年房颤患者根据依赖程度、虚弱程度和认知障碍情况的临床特征及抗栓治疗类型
J Geriatr Cardiol. 2018 Apr;15(4):268-274. doi: 10.11909/j.issn.1671-5411.2018.04.004.
7
Satisfaction with oral anticoagulants in patients with atrial fibrillation.心房颤动患者对口服抗凝剂的满意度。
Patient Prefer Adherence. 2018 Feb 19;12:267-274. doi: 10.2147/PPA.S152109. eCollection 2018.